Skip to main content
OpenTrials
Completed

NCT Number: NCT06916845

Data Collection for CV-3E AI Software Development

The goal of this clinical trial is to collect capsule images for the development of CADe software for use with the CapsoCam® Colon (CV-3E) in healthy volunteers who have been referred for colonoscopy. There will be no analysis performed as part of this protocol.

Participants will

* adhere to bowel prep instructions and dietary requirements * ingest pro-kinetic medication and CapsoCam® Colon (CV-3E) * adhere to booster regimen and dietary requirements until capsule passes * retrieve capsule with retrieval kit per instructions and mail back to sponsor * participate in follow-up phone call

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Advanced Research Institute Inc, New Port Richey, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 45-75 years of age
  • Choose to participate and must have signed the IRB-approved informed consent document.

Exclusion criteria

  • Colonoscopy or CT-colonography within the past 5 years that demonstrated no polyps
  • Colonoscopy within the past 4 years that demonstrated polyps that were removed.
  • Has contraindication for capsule endoscopy
  • Subject is suspected or diagnosed with familial adenomatous polyposis, hereditary non polyposis colon cancer, or any high-risk genetic syndrome
  • Subject is suspected or diagnosed with inflammatory bowel disease such as ulcerative colitis or Crohn's disease
  • History of incomplete colonoscopy
  • Type I or uncontrolled II Diabetes (Uncontrolled defined as HbA1C>6.4 within the past 3 months and/or with history of constipation or gastroparesis).
  • Impaired cardiac function assessed as greater than NYHA Class II
  • History of small- or large-bowel obstructive condition
  • Known history of swallowing disorder, and/or ischemic bowel disease neuropathies and/or radiation enteritis
  • Known history of NSAID enteropathy and stricture resulting from taking NSAIDs on a regular basis that, in the opinion of the Investigator, would put the subject at greater risk for capsule endoscope retention
  • Known allergy to ingredients used in bowel preparation and boosters
  • Daily and/or regular narcotic use
  • Decompensated cirrhosis
  • Prior abdominal radiation therapy
  • Diagnosis of anorexia or bulimia
  • History of or suspicion of any of the following: strictures, volvulus or intestinal obstruction, or internal hernias or abdominal surgeries that the Investigator believes should exclude the patient from study participation
  • Known or suspected megacolon
  • Scheduled to undergo MRI examination within 7 days after ingestion of the capsule
  • Has known slow gastric-emptying time or confirmed diagnosis of gastroparesis
  • Pregnant or nursing or of child-bearing potential and does not agree to practice medically acceptable methods of contraception. Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at screening.
  • Unable to follow or tolerate fasting, bowel preparation, and other study procedures
  • Any documented medical or psychological condition or significant concurrent illness which, in the Investigator's opinion, would make it unsafe for the subject to participate in this research study or would affect the validity of the study results
  • Are currently enrolled in an interventional clinical study or currently enrolled in or within the last 30 days, a pharmaceutical clinical study
  • Chronic constipation as defined by <3 bowel movements per week, or the use of routine laxatives (other than fiber) to attain regular bowel movements

Treatment and study plan

Colon Capsule

Device

All participants will swallow the CapsoCam® Colon (CV-3E) for this study.

Primary outcomes

  1. Collect Capsule Images

    Time frame: 4-6 months

    No assessment will be done for this protocol. Videos will be collected for AI development for use in future study.

Sponsors and collaborators

Lead sponsor

Capso Vision, Inc.

Industry

Registry information

Official study title

Data Collection for CapsoView AI Software Development for the CapsoCam® Colon (CV-3E)

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 8, 2025
Registry last updated
Jul 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.